• SPX
  • $5,973.10
  • 0.74 %
  • $44.06
  • DJI
  • $43,729.34
  • -0 %
  • -$0.59
  • N225
  • $39,500.37
  • 0.3 %
  • $118.96
  • FTSE
  • $8,124.57
  • -0.2 %
  • -$16.17
  • IXIC
  • $19,269.46
  • 1.51 %
  • $285.99

Sanofi enters exclusive talks with CD&R for Opella sale

By Reuters   |   Oct 21, 2024 at 01:46 AM EST
Sanofi enters exclusive talks with CD&R for Opella sale

PARIS (Reuters) -Sanofi said on Monday it had entered exclusive talks for the sale of a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R).

The French pharmaceutical company said its Opella business has been valued at around 16 billion euros ($17.38 billion), or 14 times EBITDA in 2024, and French public investment bank Bpifrance is expected to take a stake of around 2%.

French government sources had said late on Sunday that Sanofi had reached an agreement on terms of the deal after providing Paris with guarantees on maintaining jobs and production in France.

News of the sale last week had triggered criticism from government opponents over the potential loss of a strategic asset, prompting rival bidder PAI Partners to make a renewed offer for the business.

Speaking to reporters on Monday about its choice of buyer, chief executive Paul Hudson said: "We chose the group with the best capabilities and people that would help us enable the long term success of the business."

He added that while there was no timeline for how long Sanofi would be involved in Opella, "we expect to be involved and in partnership for a long time".

Opella employs 11,000 people globally and sells the popular French pain medicine Doliprane, as well as brands including Mucosolvan cough syrup, Allegra allergy treatments and Buscopan pain relief.

The proposed transaction, still subject to definitive agreements and customary statutory approvals, is expected to close in the second quarter of 2025 at the earliest, said Sanofi.

Sanofi has said it would use proceeds from the sale of Opella to provide more resources for the costly development of novel immunology and inflammation drugs.

($1 = 0.9206 euros)

(Reporting by Dominique Patton; Editing by Raju Gopalakrishnan and Shri Navaratnam)

Did you find this insightful?


We are preparing, please wait

×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.